Evaluation of the whole-process management effect of rivaroxaban for nonvalvular atrial fibrillation based on evidence-based pharmacy
基于循证药学对利伐沙班用于非瓣膜性心房颤动的全程管理效果评价

摘要

目的 观察分析基于循证药学在利伐沙班用于非瓣膜性心房颤动的全程管理效果评价。方法 纳入2023年1月至2023年12月期间接受利伐沙班治疗非瓣膜性心房颤动患者为样本，共计人数80例，依据对比实验原理将所有人员以1:1比例分成两组，一组作为对照组实施常规治疗，另一组作为观察组应用基于循证药学的全程管理措施进行干预，整理归纳不同干预后两组患者相关数据指标，观察对比差异表现，验证临床价值。结果 观察组患者栓塞事件发生率、出血事件发生率、医保人均支付费用均优于对照组，实施统计学分析对比获得P值均可见<0.05标准，有可比性。结论 非瓣膜性心房颤动患者采纳基于循证药学的全程管理措施进行干预有利于控制栓塞事件发生率、出血事件发生率，有效性、安全性更佳，同时显示出一定经济学价值，值得普及推广。

Abstract

Objective: The observation analysis is based on the evaluation of evidence-based pharmacy in rivaroxaban for non-valvular atrial fibrillation.
Methods: In January 2023 in December 2,2023, all the staff with 1:1 ratio into two groups, one as the control group, the other group as the whole management measures based on evidence-based pharmacy intervention, summarize the relevant data of the two groups after different intervention, observe the difference performance, verify the clinical value.
Results: The incidence of embolic events, bleeding events and per capita expenses of patients in the observation group were better than those in the control group, and the P values obtained by statistical analysis were <0.05, which was comparable.
Conclusion  : Patients with non-valvular atrial fibrillation adopt whole-process management measures based on evidence-based pharmacy for intervention is conducive to controlling the incidence of embolic events and bleeding events, with better effectiveness and safety, and showing certain economic value, which is worth popularizing and popularizing.